Viridian expects ~$490.9M cash as of Sept 30, 2025; preliminary, unaudited

Viridian Therapeutics, Inc.\DE

Preliminary cash, equivalents, and marketable securities of ~$490.9M as of September 30, 2025.
Figure is unaudited and may materially differ from final Q3 2025 balance sheet upon close.
Full Q3 2025 financial results not yet finalized; no revenue or EPS guidance provided.
Disclosure intended to provide early liquidity visibility ahead of complete financial report.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.